Related Experiment Video
Updated: Jul 16, 2026

Closure of a Patent Foramen Ovale (PFO): An Intervention Sequence
Published on: December 23, 2022
Patent foramen ovale and atrial septal aneurysm in cryptogenic stroke
Sujoy Ghosh1, Arjun Kumar Ghosh, Sandip Kumar Ghosh
1Ayr Hospital, Dalmellington Road, Ayr, Ayrshire, UK.
Insights
Cryptogenic strokes in young adults often involve a patent foramen ovale (PFO). While antiplatelet agents or warfarin are common treatments, PFO closure is reserved for specific cases due to inconclusive evidence on stroke prevention.
Area of Science:
- Cardiology
- Neurology
- Vascular Medicine
Background:
- Cryptogenic strokes account for up to 40% of ischemic strokes in young adults.
- Patent foramen ovale (PFO) is identified in over half of these patients, often with an atrial septal aneurysm.
- Echocardiography, particularly transesophageal echocardiography, is the primary diagnostic tool.
Purpose of the Study:
- To review the diagnostic approaches and management strategies for cryptogenic strokes in young adults.
- To evaluate the role of patent foramen ovale (PFO) in stroke etiology and recurrence.
- To discuss the current evidence regarding PFO closure versus medical therapy for stroke prevention.
Main Methods:
- Literature review of studies investigating cryptogenic stroke, PFO, and atrial septal aneurysm.
- Analysis of diagnostic methods, including echocardiography.
- Examination of treatment outcomes for antiplatelet agents, warfarin, and percutaneous PFO closure.
Main Results:
- Patent foramen ovale (PFO) is a frequent finding in cryptogenic strokes among young individuals.
- Low-risk patients are typically managed with antiplatelet agents, while high-risk patients receive warfarin.
- Data on the efficacy of PFO closure for preventing recurrent stroke remain inconclusive.
Conclusions:
- Patent foramen ovale (PFO) is a significant consideration in the workup of cryptogenic strokes in young adults.
- Medical therapy (antiplatelets or warfarin) is the standard initial treatment based on risk stratification.
- Percutaneous PFO closure is considered for recurrent stroke or medical therapy intolerance, despite limited evidence of its preventative efficacy.
Abstract:
Up to 40% of acute ischaemic strokes in young adults are cryptogenic in nature, that is, no cause is determined. In more than half of these patients, patent foramen ovale (PFO) is seen along with an increased incidence of atrial septal aneurysm. The commonest method of investigation is echocardiography (preferably transoesophageal echocardiography). On the basis of available evidence, low risk patients are treated with antiplatelet agents and high risk patients with warfarin. There are inconclusive data on the efficacy of PFO closure to prevent stroke recurrence. However, if there is recurrent stroke or intolerance to medical therapy, percutaneous closure is carried out.
Related Concept Videos
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Hemorrhagic Stroke ll: Pathophysiology
The Arch of Aorta
Encircling the heart, the coronary arteries form a ring-like structure before...
Ischemic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction
Aneurysm I: Introduction

